Nunzio Filardi

Suggest Changes
Learn More
OBJECTIVE Azacitidine is the standard of care for higher-risk myelodysplastic syndromes (MDS). We evaluated factors affecting the outcome of azacitidine treatment in 196 'real-world' patients,(More)
  • 1